Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2010 Scrip 100 - Can China retain its API sourcing appeal?

This article was originally published in Scrip

Executive Summary

China has a burgeoning API manufacturing base, albeit one focused largely on achieving quick profits in the domestic sector. Robert Kennedy's analysis reveals a striking number of Chinese companies that are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

You may also be interested in...



Commentary: China's changing role in the global pharmaceutical supply chain

In preparation for the 2008 Olympic and Paralympic games, the Chinese government shut down a large number of factories in and around Beijing in an effort to improve the air quality for the athletes and spectators. With the implementation of more stringent environmental health and safety (EHS) regulations, many of these factory closures will be permanent because the facilities cannot conform to new waste water treatment standards. In the past, the Chinese government would not have shut down a major manufacturer and tax generator just because they did not meet all of the EHS requirements.

Topics

Related Companies

UsernamePublicRestriction

Register

AG032826

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel